Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03280303 · ClinicalTrials.gov registry record
Palbociclib in Real World Practice
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 1,285
- Enrollment target
NCT03280303: Completed study, sponsored by Pfizer.
NCT03280303 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 1,285 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03280303 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 1,285 participants
- Enrollment target
Study Summary
This Non-Interventional Study will describe and analyze the clinical use of palbociclib in routine clinical practice in the treatment of advanced breast cancer.
Primary Outcome
Real world tumor response included complete response (CR), Partial response (PR), Stable disease (SD), Progressive Disease (PD), and was determined by physician based on imaging, biopsies, biomarkers, and/or clinical judgment. Response as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria may not be available for all participants. rwTR was derived as the best tumor response recorded from the palbociclib combination treatment start date until the first documentation of pro
Interventions
- OTHER non-interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,285 participants |
| Start Date | 2017-01-04 |
| Est. Completion | 2022-12-22 |
What the finished NCT03280303 record still lists
NCT03280303 is an observational study that tracks outcomes without assigning an intervention. Its 1,285 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which non-interventional is the first listed.
NCT03280303 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03280303 about?
NCT03280303 is a clinical study titled "Palbociclib in Real World Practice". This Non-Interventional Study will describe and analyze the clinical use of palbociclib in routine clinical practice in the treatment of advanced breast cancer.
What is the current status of trial NCT03280303?
This trial is currently completed. The enrollment target is 1,285 participants. The study started on 2017-01-04. Estimated completion is 2022-12-22.
What interventions are being tested in trial NCT03280303?
The interventions under investigation include: non-interventional (OTHER).
Who is sponsoring clinical trial NCT03280303?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06626022 · 1,284 participants · Phase 3
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
- NCT05595642 · 1,290 participants · Phase 3
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
- NCT03970447 · 1,280 participants · Phase 2
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- NCT06468228 · 1,280 participants · Phase 3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI